5-Hydroxytryptamine receptor agonist

FDA, Combined Use of 5-Hydroxytryptamine Receptor Agonists (Triptans), Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) May Result in Life-Threatening Serotonin Syndrome , FDA Public Health Advisory (2006) http //www.fda.gov/Cder/Drug/advisory/ S SRI S S200607.htm... 

A life-threatening condition, when selective serotonin reuptake inhibitors (SSRIs) and 5-hydroxytryptamine receptor agonists (triptans) are used together. However, many other drugs have been implicated (see below). Signs and symptoms of serotonin syndrome include the following ... 

Arvidsson LE, Hacksell U, Johansson AM, et al. 8-Hydroxy-2-(alkylamino) tetralins and related compounds as central 5-hydroxytryptamine receptor agonists. J Med Chem 1984 27 45-51. 

Mork A, Geisler A. 5-Hydroxytryptamine receptor agonists influence calcium-stimulated adenylate cyclase activity in the cerebral cortex and hippocampus of the rat. Eur J Pharmacol 1990 175 237-244. 

Another type of anxiolytic is buspirone, which appears to work principally as a partial agonist at 5-HTia receptors (see 5-HYDROXYTRYPTAMINE receptor agonists). Examples under development include tandospirone, zalospirone and zolmitriptan. 

BIMU 1 is a benzimidazole-carboxamide derivative, a selective (S-HT -subtype) 5-hydroxytryptamine receptor AGONIST. It has antiemetic properties, and is used as a pharmacological tool. 

HYDROXYTRYPTAMINE RECEPTOR AGONIST that has PSYCHOTROPIC (hallucinogenic) properties, dimethoxystrychnine brucine, dimethyladamantanamine memantine, dimethylbiochanin B daidzein. P-dimethylcysteine penicillamine. 

AGONIST or a-ADRENOCEPTOR ANTAGONIST, weak DOPAMINE RECEPTOR ANTAGONIST and (5-HT,) 5-HYDROXYTRYPTAMINE RECEPTOR AGONIST. It is a VASOCONSTRICTOR used in acute antimigraine treatment. It is oxytocic and has been used as an ABORTIFACIENT. Also. it is a component of Cafergot ... 

BMY 13805-1 MJ 13805) is one of the azaspirone group structurally related to buspirone and with similar properties. It is a 5-hydroxytryptamine receptor agonist, a partial agonist at the 5HTi receptor subtype. It is a novel ANXIOLYTIC under investigation for treatment of anxiety and depression. 

HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS act at one or more of the 14 or so known 5-HT receptors (see 5-hydroxytryptamine receptor agonists), and commonly have actions on other systems (especially monoaminergic ones). 

Many other agents have actions on the uterus, including MUSCARINIC CHOLINOCEPTOR AGONISTS 5-hydroxytryptamine (5-HT2) agonists (see 5-hydroxytryptamine receptor agonists) a-adrenoceptor agonists (which can contract the uterus) bradykinin receptor agonists (Bj-receptors). However, these actions are not selective and so are not harnessed therapeutically. 

Conversely, proaggregatory agents induce this mechanism of adhesion (e.g. thromboxane. ADP, 5-HT and PAF). 5-HT (serotonin) stimulates platelet aggregation and is. as its name implies, a vasoconstrictor in many blood vessels. It is actively taken up into platelets, and released on insult. See 5-HYDROXYTRYPTAMINE RECEPTOR AGONISTS. 

U 92016A is a benzindole derivative, a potent and selective (5-HT,A-subtype) 5-hydroxytryptamine receptor agonist. It is used as a pharmacological tool, ubenimex bestatin. 

Monoester 4-(methoxycarbonyl)bicyclo[2.2.1]heptane-l-carboxylic acid 59 (Figure 4.17) is a building block of many potential therapeutic candidates for inhibitors of 11-p-hydroxysteroid dehydrogenase type 1 enzyme and their use in the treatment of non-insulin-dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and CNS disorders. It is also required for the synthesis of 5-hydroxytryptamine receptor agonists, useful for the treatment of anxiety disorders and schizophrenia [90,91]. 

---